Although clinical studies have demonstrated that TP53/RB1–deficient SCNPCs, as well as small cell lung cancer, generally show high response rate to platinum chemotherapy, many patients respond for relatively short periods of time, and patients almost universally succumb to recurrent disease (29, 30). This evidence concerns the gene TP53 and small cell lung carcinoma.